Votrient (pazopanib) — United Healthcare
Chondrosarcoma
Initial criteria
- Diagnosis of chondrosarcoma AND disease is metastatic and widespread
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Votrient therapy
Approval duration
12 months